AGIO (Agios Pharmaceuticals, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by AGIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-06 | Sarah Gheuens | Chief Medical Officer | Sell | — | — |
| 2026-08-06 | Sarah Gheuens | Chief Medical Officer | Sell | — | — |
| 2026-07-10 | Jay T. Backstrom | Director | A | — | — |
| 2026-07-02 | Sarah Gheuens | Chief Medical Officer | MIXED | — | — |
| 2026-06-23 | Adams Catherine Owen | Director | M | — | — |
| 2026-06-23 | Jay T. Backstrom | Director | A | — | — |
| 2026-06-23 | Krishnan Viswanadhan | Chief Strategy and Operations | MIXED | — | — |
| 2026-06-23 | Sarah Gheuens | Chief Medical Officer | MIXED | — | — |
| 2026-06-23 | Cecilia Jones | Chief Financial Officer | MIXED | — | — |
| 2026-06-23 | Brian Goff | Chief Executive Officer | MIXED | — | — |
| 2026-06-23 | JACQUALYN A FOUSE | Director | M | — | — |
| 2026-06-23 | Rahul D. Ballal | Director | M | — | — |
| 2026-06-23 | James William Burns | Chief Legal Officer | MIXED | — | — |
| 2026-06-23 | David Scadden | Director | M | — | — |
| 2026-06-23 | Cynthia Smith | Director | M | — | — |
| 2026-06-23 | JEFFREY D CAPELLO | Director | M | — | — |
| 2026-06-23 | Kaye I Foster-Cheek | Director | M | — | — |
| 2026-06-23 | Maykin Ho | Director | M | — | — |
| 2026-06-23 | Tsveta Milanova | Chief Commercial Officer | MIXED | — | — |
| 2026-06-16 | Adams Catherine Owen | Director | M | — | — |
| 2026-06-16 | JEFFREY D CAPELLO | Director | M | — | — |
| 2026-04-06 | Tsveta Milanova | Chief Commercial Officer | MIXED | — | — |
| 2026-04-06 | James William Burns | Chief Legal Officer | MIXED | — | — |
| 2026-04-06 | Cecilia Jones | Chief Financial Officer | MIXED | — | — |
| 2026-04-06 | Krishnan Viswanadhan | Chief Corp Dev & Strategy | MIXED | — | — |
| 2026-04-06 | Brian Goff | Chief Executive Officer | MIXED | — | — |
| 2026-04-06 | Sarah Gheuens | Chief Medical Officer | MIXED | — | — |
| 2026-03-09 | Krishnan Viswanadhan | Chief Corp Dev & Strategy | MIXED | — | — |
| 2026-03-05 | Theodore James Washburn Jr. | Principal Accounting Officer | Sell | — | — |
| 2026-03-03 | Krishnan Viswanadhan | Chief Corp Dev & Strategy | A | — | — |
| 2026-03-03 | Theodore James Washburn Jr. | Principal Accounting Officer | MIXED | — | — |
| 2026-03-03 | Cecilia Jones | Chief Financial Officer | MIXED | — | — |
| 2026-03-03 | James William Burns | Chief Legal Officer | MIXED | — | — |
| 2026-03-03 | Sarah Gheuens | Chief Medical Officer | MIXED | — | — |
| 2026-03-03 | Brian Goff | Chief Executive Officer | MIXED | — | — |
| 2026-03-03 | Tsveta Milanova | Chief Commercial Officer | MIXED | — | — |
| 2026-01-07 | Tsveta Milanova | Chief Commercial Officer | MIXED | — | — |
| 2026-01-02 | Sarah Gheuens | Chief Medical Officer | MIXED | — | — |
| 2026-01-02 | James William Burns | Chief Legal Officer | MIXED | — | — |
| 2026-01-02 | Tsveta Milanova | Chief Commercial Officer | MIXED | — | — |
| 2026-01-02 | Cecilia Jones | Chief Financial Officer | MIXED | — | — |
| 2026-01-02 | Brian Goff | Chief Executive Officer | MIXED | — | — |
| 2025-11-14 | David Scadden | Director | MIXED | — | — |
| 2025-11-13 | Sarah Gheuens | Chief Medical Officer | MIXED | — | — |
| 2025-11-03 | Sarah Gheuens | Chief Medical Officer | MIXED | — | — |
| 2025-10-29 | Sarah Gheuens | Chief Medical Officer | MIXED | — | — |
| 2025-10-10 | David Scadden | Director | MIXED | — | — |
| 2025-10-02 | David Scadden | Director | MIXED | — | — |
| 2025-09-30 | Cecilia Jones | Chief Financial Officer | MIXED | — | — |
| 2025-09-09 | Theodore James Washburn Jr. | Principal Accounting Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 6,718,433 | — |
| — | 10%+ Owner | 5,788,750 | — |
| — | 10%+ Owner | 3,860,738 | — |
| — | 10%+ Owner | 3,088,590 | — |
| — | 10%+ Owner | 3,070,090 | — |
| — | Director | 944,581 | — |
| — | Director | 397,014 | — |
| — | Chief Executive Officer | 177,604 | — |
| — | Director | 154,156 | — |
| — | Chief Operating Officer | 120,834 | — |
| — | Director | 118,404 | — |
| — | Director | 101,654 | — |
| — | Chief Scientific Officer | 86,788 | — |
| — | Chief Financial Officer | 54,998 | — |
| — | Chief Medical Officer | 54,645 | — |
| — | Chief Legal Officer | 52,586 | — |
| — | Chief Commercial Officer | 50,091 | — |
| — | Director | 30,028 | — |
| — | Chief Financial Officer | 24,272 | — |
| — | Chief Financial Officer | 22,953 | — |
| — | Director | 20,419 | — |
| — | Director | 19,848 | — |
| — | Chief Scientific Officer | 18,793 | — |
| — | Chief Medical Officer | 15,487 | — |
| — | Director | 15,230 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AGIO quote page; the site-wide leaderboard is on the insider transactions hub.